Black Diamond Therapeutics, Inc.
NASDAQBlack Diamond Therapeutics heads into its May 8 earnings release as a binary-catalyst story: cash runway and clinical momentum matter far more here than any quarterly numbers. Analysts are leaning constructively into the print, though views diverge sharply on risk. The most recent move came from BTIG on April 29, raising its target to $11 while maintaining a Buy rating — a signal…
Snapshot as of 23 Jun 2026
Black Diamond Therapeutics heads into its May 8 earnings release as a binary-catalyst story: cash runway and clinical momentum matter far more here than any quarterly numbers. Analysts are leaning constructively into…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BDTX — free to start on ORTEX.
Sign up for free →Open BDTX on ORTEX